TDOC
Teladoc Health, Inc.
NYSE · Healthcare · Medical - Healthcare Information Services · US
$9.65
+8.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5B | 2.5B | 2.6B | 2.6B | 2.4B |
| Cost of Revenue | 662.0M | 771.6M | 751.3M | 760.0M | 744.0M |
| Gross Profit | 1.8B | 1.8B | 1.8B | 1.8B | 1.7B |
| Operating Expenses | |||||
| R&D Expense | 267.9M | 277.9M | 307.3M | 348.5M | 333.6M |
| SG&A Expense | 1.1B | 1.1B | 1.3B | 1.4B | 1.3B |
| General & Admin Expense | 421.9M | 431.9M | 435.5M | 464.7M | 449.9M |
| Selling & Marketing Expense | 668.9M | 653.4M | 910.8M | 902.6M | 850.7M |
| Other Expenses | 597.4M | 658.2M | 1.2B | 375.1M | 13.7B |
| Total Operating Expenses | 2.0B | 2.0B | 2.8B | 2.1B | 15.3B |
| Cost and Expenses | 2.6B | 2.8B | 3.6B | 2.9B | 16.1B |
| Operating Income (EBIT) | (149.9M) | (263.0M) | (1.0B) | (248.6M) | (13.7B) |
| Non-Operating | |||||
| Interest Income | 58.5M | 36.8M | 57.1M | 46.8M | 12.7M |
| Interest Expense | 20.4M | 19.7M | 23.8M | 22.3M | 21.9M |
| Net Interest Income | 38.2M | 17.1M | 33.3M | 24.5M | (9.3M) |
| Other Non-Op Income/Expense | (8.7M) | 27.4M | 27.2M | 28.9M | (10.1M) |
| Non-Operating Income (excl Interest) | (14.1M) | (47.1M) | (812.1M) | (38.1M) | (13.4B) |
| EBT (Pre-Tax Income) | (158.7M) | (235.5M) | (993.7M) | (219.6M) | (13.7B) |
| Income Tax Expense | (3.8M) | (35.2M) | 7.6M | 760.0K | (3.8M) |
| Bottom Line | |||||
| Net Income | (154.8M) | (200.3M) | (1.0B) | (220.4M) | (13.7B) |
| Earnings from Cont. Ops | (154.8M) | (200.3M) | (1.0B) | (220.4M) | (13.7B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (154.8M) | (200.3M) | (1.0B) | (220.4M) | (13.7B) |
| Per Share | |||||
| Basic EPS | ($0.86) | ($1.14) | ($5.87) | ($1.36) | ($84.60) |
| Diluted EPS | ($0.86) | ($1.14) | ($5.87) | ($1.34) | ($84.60) |
| Revenue Per Share | $13.57 | $14.36 | $15.07 | $16.05 | $14.91 |
| Shares | |||||
| Basic Shares Outstanding | 181.9M | 176.2M | 170.6M | 162.2M | 161.5M |
| Diluted Shares Outstanding | 181.9M | 176.2M | 170.6M | 164.6M | 161.5M |
| Profitability Metrics | |||||
| EBITDA | 236.1M | 147.3M | 174.1M | 138.2M | 50.3M |
| D&A | 371.9M | 363.1M | 382.8M | 348.7M | 267.8M |
| EBIT | (135.8M) | (215.8M) | (208.8M) | (210.5M) | (217.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026